A., Aprikian, O., von Eynatten, M., & Johansen, O
Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
Poole, R
GLP-1 agonists work by mimicking our natural hormone
Variants in your GLP1R gene (rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) influence how strongly you respond to GLP-1 and how fast appetite returns after stopping
Resist the urge to swallow for as long as possible